RIVM will calculate temporary background value for PFAS in soil In the coming weeks, RIVM will derive a temporary background value for PFAS in Dutch soil. This will be done based on measurement data from the provinces in the Netherlands.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
New method for toxicological assessment of perfluoro mixtures Perfluoro (PFAS) is a group of substances that contains PFOS, PFOA and GenX. Perfluoro substances often occur as pollution in ground water and drinking water.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
Proposal for water quality standards for PFOA RIVM proposes water quality standards for perfluoro octanoic acid (PFOA). PFOA is a man-made chemical that is used to protect surfaces.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
RIVM seeks dialogue with Industry for safe and green chemistry RIVM would like to explore possibilities to eliminate obstacles during innovation of green chemistry with industry.